AnaptysBio (NASDAQ:ANAB) Earns "Outperform" Rating from Wedbush

AnaptysBio (NASDAQ:ANAB - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at Wedbush in a research note issued to investors on Wednesday, RTT News reports. They currently have a $42.00 price target on the biotechnology company's stock. Wedbush's target price would suggest a potential upside of 89.10% from the stock's previous close.

Other equities analysts have also issued reports about the stock. Guggenheim boosted their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a report on Monday, October 21st. UBS Group boosted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. Truist Financial boosted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of AnaptysBio in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $55.45.

AnaptysBio Stock Up 11.7 %

NASDAQ:ANAB traded up $2.33 on Wednesday, hitting $22.21. The stock had a trading volume of 678,194 shares, compared to its average volume of 347,106. The stock has a market cap of $609.31 million, a price-to-earnings ratio of -3.54 and a beta of -0.24. The company has a fifty day moving average price of $33.59 and a two-hundred day moving average price of $29.94. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. As a group, analysts anticipate that AnaptysBio will post -6.84 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company's stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Paul F. Lizzul sold 1,500 shares of the company's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the company's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares of the company's stock, valued at approximately $189,333.04. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,440 shares of company stock valued at $892,936. Insiders own 33.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ANAB. Ensign Peak Advisors Inc boosted its holdings in shares of AnaptysBio by 74.4% in the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company's stock valued at $1,898,000 after acquiring an additional 32,313 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of AnaptysBio in the first quarter valued at about $420,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of AnaptysBio in the first quarter valued at about $1,221,000. Assenagon Asset Management S.A. boosted its holdings in shares of AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock valued at $15,927,000 after acquiring an additional 168,813 shares in the last quarter. Finally, Alpha DNA Investment Management LLC purchased a new stake in shares of AnaptysBio in the second quarter valued at about $399,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.